Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
Key Financial Performance
Cash, cash equivalents and marketable securities $669.9 million as of September 30, 2025, compared to $861.7 million as of December 31, 2024. The decrease is attributed to operational expenses and investments in the clinical pipeline.
Collaboration revenue $13.8 million during the third quarter of 2025 compared to $9.1 million during the prior year quarter. The $4.7 million increase was mainly driven by cost reimbursements related to the collaboration with Regeneron Pharmaceuticals.
R&D expenses $94.7 million during the third quarter of 2025 compared to $123.4 million during the prior year quarter. The $28.7 million decrease was primarily driven by reductions in employee-related expenses, stock-based compensation, research materials, and contracted services, offset by an increase in the advancement of lead programs.
Stock-based compensation expense (R&D) $12.2 million for the third quarter of 2025.
G&A expenses $30.5 million during the third quarter of 2025, unchanged from the prior year quarter. Stock-based compensation expense included within G&A was $7.4 million for the third quarter of 2025.
Net loss $101.3 million for the third quarter of 2025, down from $135.7 million for the prior year quarter. The reduction is attributed to lower R&D expenses and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
nex-z: Phase III clinical trials (MAGNITUDE and MAGNITUDE-2) for ATTR amyloidosis are paused due to a patient safety incident. The FDA has placed a clinical hold on these trials. Despite challenges, the company remains optimistic about nex-z's potential to address unmet needs in ATTR amyloidosis.
lonvo-z: Phase III clinical trial (HAELO) for hereditary angioedema (HAE) completed enrollment in less than 9 months. Top-line data expected by mid-2026, with a potential U.S. commercial launch in the first half of 2027. The product aims to redefine HAE treatment by eliminating attacks with a single dose.
Financial Position: Cash, cash equivalents, and marketable securities totaled $669.9 million as of September 30, 2025, down from $861.7 million at the end of 2024. The company raised $115 million through its ATM facility and implemented restructuring initiatives to extend its cash runway into mid-2027.
Collaboration Revenue: Collaboration revenue increased to $13.8 million in Q3 2025 from $9.1 million in Q3 2024, driven by cost reimbursements from Regeneron Pharmaceuticals.
R&D and G&A Expenses: R&D expenses decreased to $94.7 million in Q3 2025 from $123.4 million in Q3 2024, while G&A expenses remained flat at $30.5 million. The company expects a year-over-year decline in GAAP operating expenses of at least 10%.
Restructuring Initiatives: Implemented in early 2025 to reduce costs and extend cash runway, supporting the company's focus on its lead programs and future capabilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical Hold on MAGNITUDE and MAGNITUDE-2 Trials: The FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 trials following a patient's death and liver-related adverse events. This has paused patient dosing and screening, delaying the development timeline for nex-z and impacting milestone guidance.
Safety Concerns with nex-z: Grade 4 liver transaminase elevations have been reported in less than 1% of patients in the MAGNITUDE trial, raising concerns about the safety profile of nex-z. Additional monitoring and risk mitigation strategies are being considered.
Regulatory Uncertainty: The company is awaiting the FDA's formal clinical hold letter and must engage with global regulatory authorities to address concerns and requirements, creating uncertainty around the resumption of trials and future approvals.
Financial Sustainability: The company reported a significant decrease in cash reserves from $861.7 million to $669.9 million over nine months, despite raising $115 million. While the cash runway extends to mid-2027, financial pressures could intensify if delays persist.
Dependence on lonvo-z Commercialization: The company is heavily reliant on the successful commercialization of lonvo-z for HAE, with plans for a U.S. launch in 2027. Any setbacks in this program could further strain financial and operational resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
nex-z Phase III clinical trials (MAGNITUDE and MAGNITUDE-2): The company is working with global regulatory authorities to develop a plan to resume enrollment in the trials after a clinical hold due to a patient safety incident. The company remains committed to the potential of nex-z to address unmet needs in ATTR amyloidosis and plans to provide updates once a plan is finalized.
lonvo-z Phase III clinical trial (HAELO): Enrollment was completed in September 2025, and the company plans to share top-line data by mid-2026. A BLA submission to the FDA is anticipated in the second half of 2026, with a commercial launch in the U.S. expected in the first half of 2027. The company believes lonvo-z could redefine the HAE treatment landscape by eliminating attacks and the need for other medications for most patients with a single dose.
Financial outlook: The company has extended its cash runway into mid-2027, supported by restructuring initiatives and funds raised from its ATM facility. This timeline aligns with the anticipated commercial launch of lonvo-z in the U.S.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the initial hypothesis for the reason behind liver enzyme elevation in the study?
A:Management stated that they can only speculate and are not going to do so at this time. They noted that the case was distinct and involved a complicated clinical course with comorbidities that may have influenced the outcome. They also mentioned that the incidence of liver enzyme elevation was less than 1% across the study of over 650 patients.
Q:Can you provide details about the comorbidities of the patient and whether the patient was managed in the U.S. or ex-U.S.?
A:Management declined to provide details about the comorbidities or the geography of the patient. They assured that the patient received excellent medical care and mentioned ongoing work to analyze data and develop risk mitigation strategies.
Q:How many ATTR patients are currently within the 3- to 5-week post-dose window in the study?
A:Management did not provide precise numbers but stated that the vast majority of patients have passed through this window, and the number of patients in this phase is decreasing daily.
Q:What is the impact of the clinical hold on the company's operating expenses and financial runway?
A:Management stated that while the clinical hold prevents new patient enrollment, the study continues with over 650 patients in MAGNITUDE and 47 in MAGNITUDE-2. They noted that incremental costs per patient are reduced during the hold, and they do not foresee a substantial shift in operating or cash needs. They will reassess timelines and costs once the hold is lifted.
Q:Are there any liver-related comorbidities in the patient, and how many cases of Grade 4 liver enzyme elevation have occurred?
A:Management did not disclose details about liver-related comorbidities. They reiterated that less than 1% of the 650+ patients experienced Grade 4 liver enzyme elevation and declined to provide precise case numbers.
Q:Can anything be done preclinically to disprove causation between the treatment and the safety event?
A:Management stated that they are conducting a comprehensive analysis of all available data to identify potential risks. They are awaiting the FDA's clinical hold letter to determine next steps.
Q:Why was the ATM (At-The-Market) financing executed, and is it the path forward for raising additional cash?
A:Management explained that the ATM is a tool within their financing strategy and not a primary approach. They emphasized having multiple options for raising funds, including collaborations, debt structures, and creative financing opportunities.
Q:Are there notable differences in baseline characteristics between MAGNITUDE and MAGNITUDE-2?
A:Management stated that the primary difference is the indication: MAGNITUDE focuses on cardiomyopathy, while MAGNITUDE-2 focuses on polyneuropathy. Other differences are minimal.
Q:What are the next steps apart from the FDA letter?
A:Management is conducting a comprehensive analysis of clinical, preclinical, and manufacturing data. They are awaiting the FDA letter to determine specific requirements and will work closely with the FDA to address concerns and mitigate risks.
Q:What are the differences in the construct between the ATTR candidate and the HAE candidate?
A:Management explained that the lipid nanoparticle (LNP) is the same for both, but the guide RNA differs, leading to different outcomes. The diseases and patient populations are distinct.
Q:Will the patient death in the TTR trial affect the commercial opportunity for the HAE indication?
A:Management stated that it is too early to speculate on the commercial impact. They emphasized the distinct nature of the two indications and pointed to upcoming data presentations for more insights.
Q:What is the cause of death for the patient in the cardiomyopathy trial?
A:Management stated that they are awaiting additional insights and will share information once all final materials are in hand.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to several questions, including details about the patient's comorbidities, the geography of care, precise numbers of Grade 4 liver enzyme cases, and the cause of death. They also did not provide specific financial guidance or timelines for resolving the clinical hold, citing ongoing analyses and pending information from the FDA.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AHA Scientific
ALT level
AST ALT
ATTR MAGNITUDE
Allergy Asthma
American College
Annual Scientific
Asthma Immunology
BLA FDA
College Allergy
Communications Intellia
Corporate Communications
Enrollment month
FDA hold
FDA launch
Fredette Vice
Grade liver
HAE course
III trial
MAGNITUDE Phase
MAGNITUDE patient
Phase III
dosing MAGNITUDE
factor
interest safety
lab
limit
liver transaminase
lonvo
mortality
onetime treatment
patient MAGNITUDE
patient dosing
potential
start
transaminase elevation
NTLA Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call revealed an increase in revenue but also a widening net loss due to higher R&D expenses. The cash reserves are decreasing, raising concerns about financial sustainability. The Q&A section did not provide clarity on management's responses, which may contribute to uncertainty. Despite a positive revenue growth, the financial health and lack of strategic updates suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8%.
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
NTLA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
